Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Review
  • Published:

Analysis of the genome to personalize therapy for melanoma

Oncogene volume 29, pages 5545–5555 (2010)Cite this article

Subjects

Abstract

The treatment of cancer is being revolutionized by an improved understanding of the genetic events that occur in tumors. Advances in the understanding of the prevalence and patterns of mutations in melanoma have recently led to impressive results in trials of personalized, targeted therapies for this disease. In this review, we will discuss the molecular targets that have been validated clinically, additional genetic events that are candidates for future trials, and the challenges that remain to improve outcomes further in this aggressive disease.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

Similar content being viewed by others

References

  • Akslen LA, Puntervoll H, Bachmann IM, Straume O, Vuhahula E, Kumar R et al. (2008). Mutation analysis of the EGFR-NRAS-BRAF pathway in melanomas from black Africans and other subgroups of cutaneous melanoma. Melanoma Res 18: 29–35.

    CAS  PubMed  Google Scholar 

  • Almoguera C, Shibata D, Forrester K, Martin J, Arnheim N, Perucho M . (1988). Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell 53: 549–554.

    Article  CAS  PubMed  Google Scholar 

  • Antonescu CR, Busam KJ, Francone TD, Wong GC, Guo T, Agaram NP et al. (2007). L576P KIT mutation in anal melanomas correlates with KIT protein expression and is sensitive to specific kinase inhibition. Int J Cancer 121: 257–264.

    CAS  PubMed  Google Scholar 

  • Ashida A, Takata M, Murata H, Kido K, Saida T . (2009). Pathological activation of KIT in metastatic tumors of acral and mucosal melanomas. Int J Cancer 124: 862–868.

    CAS  PubMed  Google Scholar 

  • Atkins MB, Kunkel L, Sznol M, Rosenberg SA . (2000). High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: long-term survival update. Cancer J Sci Am 6 (Suppl 1): S11–S14.

    PubMed  Google Scholar 

  • Atkins MB, Lotze MT, Dutcher JP, Fisher RI, Weiss G, Margolin K et al. (1999). High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 17: 2105–2116.

    CAS  PubMed  Google Scholar 

  • Baguley BC . (2010). Multidrug resistance in cancer. Methods Mol Biol 596: 1–14.

    CAS  PubMed  Google Scholar 

  • Baker M . (2008). Melanoma in mice casts doubt on scarcity of cancer stem cells. Nature 456: 553.

    CAS  PubMed  Google Scholar 

  • Bastian BC, LeBoit PE, Hamm H, Brocker EB, Pinkel D . (1998). Chromosomal gains and losses in primary cutaneous melanomas detected by comparative genomic hybridization. Cancer Res 58: 2170–2175.

    CAS  PubMed  Google Scholar 

  • Beadling C, Jacobson-Dunlop E, Hodi FS, Le C, Warrick A, Patterson J et al. (2008). KIT gene mutations and copy number in melanoma subtypes. Clin Cancer Res 14: 6821–6828.

    CAS  PubMed  Google Scholar 

  • Birck A, Ahrenkiel V, Zeuthen J, Hou-Jensen K, Guldberg P . (2000). Mutation and allelic loss of the PTEN/MMAC1 gene in primary and metastatic melanoma biopsies. J Invest Dermatol 114: 277–280.

    CAS  PubMed  Google Scholar 

  • Bonnet D, Dick JE . (1997). Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 3: 730–737.

    Article  CAS  PubMed  Google Scholar 

  • Bos JL . (1989). ras oncogenes in human cancer: a review. Cancer Res 49: 4682–4689.

    CAS  PubMed  Google Scholar 

  • Bos JL, Fearon ER, Hamilton SR, Verlaan-de Vries M, van Boom JH, van der Eb AJ et al. (1987). Prevalence of ras gene mutations in human colorectal cancers. Nature 327: 293–297.

    CAS  PubMed  Google Scholar 

  • Bos JL, Toksoz D, Marshall CJ, Verlaan-de Vries M, Veeneman GH, van der Eb AJ et al. (1985). Amino-acid substitutions at codon 13 of the N-ras oncogene in human acute myeloid leukaemia. Nature 315: 726–730.

    CAS  PubMed  Google Scholar 

  • Brazil DP, Park J, Hemmings BA . (2002). PKB binding proteins. Getting in on the Akt. Cell 111: 293–303.

    CAS  PubMed  Google Scholar 

  • Brose MS, Volpe P, Feldman M, Kumar M, Rishi I, Gerrero R et al. (2002). BRAF and RAS mutations in human lung cancer and melanoma. Cancer Res 62: 6997–7000.

    CAS  PubMed  Google Scholar 

  • Cantley LC . (2002). The phosphoinositide 3-kinase pathway. Science 296: 1655–1657.

    CAS  PubMed  Google Scholar 

  • Carpten JD, Faber AL, Horn C, Donoho GP, Briggs SL, Robbins CM et al. (2007). A transforming mutation in the pleckstrin homology domain of AKT1 in cancer. Nature 448: 439–444.

    CAS  PubMed  Google Scholar 

  • Chudnovsky Y, Khavari PA, Adams AE . (2005). Melanoma genetics and the development of rational therapeutics. J Clin Invest 115: 813–824.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Cohen Y, Goldenberg-Cohen N, Parrella P, Chowers I, Merbs SL, Pe'er J et al. (2003). Lack of BRAF mutation in primary uveal melanoma. Invest Ophthalmol Vis Sci 44: 2876–2878.

    PubMed  Google Scholar 

  • Courtney KD, Corcoran RB, Engelman JA . (2010). The PI3K pathway as drug target in human cancer. J Clin Oncol 28: 1075–1083.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Cruz III F, Rubin BP, Wilson D, Town A, Schroeder A, Haley A et al. (2003). Absence of BRAF and NRAS mutations in uveal melanoma. Cancer Res 63: 5761–5766.

    CAS  PubMed  Google Scholar 

  • Curtin JA, Busam K, Pinkel D, Bastian BC . (2006). Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol 24: 4340–4346.

    CAS  PubMed  Google Scholar 

  • Curtin JA, Fridlyand J, Kageshita T, Patel HN, Busam KJ, Kutzner H et al. (2005). Distinct sets of genetic alterations in melanoma. N Engl J Med 353: 2135–2147.

    CAS  PubMed  Google Scholar 

  • Dankort D, Curley DP, Cartlidge RA, Nelson B, Karnezis AN, Damsky Jr WE et al. (2009). Braf(V600E) cooperates with Pten loss to induce metastatic melanoma. Nat Genet 41: 544–552.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S et al. (2002). Mutations of the BRAF gene in human cancer. Nature 417: 949–954.

    CAS  PubMed  Google Scholar 

  • Davies M, Hennessy B, Mills GB . (2006). Point mutations of protein kinases and individualised cancer therapy. Expert Opin Pharmacother 7: 2243–2261.

    CAS  PubMed  Google Scholar 

  • Davies MA, Stemke-Hale K, Lin E, Tellez C, Deng W, Gopal YN et al. (2009). Integrated molecular and clinical analysis of AKT activation in metastatic melanoma. Clin Cancer Res 15: 7538–7546.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Downward J . (2003). Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer 3: 11–22.

    CAS  PubMed  Google Scholar 

  • Dry JR, Pavey S, Pratilas CA, Harbron C, Runswick S, Hodgson D et al. (2010). Transcriptional pathway signatures predict MEK addiction and response to selumetinib (AZD6244). Cancer Res 70: 2264–2273.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Eaves CJ . (2008). Cancer stem cells: here, there, everywhere? Nature 456: 581–582.

    CAS  PubMed  Google Scholar 

  • Eisen T, Ahmad T, Flaherty KT, Gore M, Kaye S, Marais R et al. (2006). Sorafenib in advanced melanoma: a phase II randomized discontinuation trial analysis. Br J Cancer 95: 581–586.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Emery CM, Vijayendran KG, Zipser MC, Sawyer AM, Niu L, Kim JJ et al. (2009). MEK1 mutations confer resistance to MEK and B-RAF inhibition. Proc Natl Acad Sci USA 106: 20411–20416.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Engelman JA, Chen L, Tan X, Crosby K, Guimaraes AR, Upadhyay R et al. (2008). Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nat Med 14: 1351–1356.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Ernst DS, Eisenhauer E, Wainman N, Davis M, Lohmann R, Baetz T et al. (2005). Phase II study of perifosine in previously untreated patients with metastatic melanoma. Invest New Drugs 23: 569–575.

    CAS  PubMed  Google Scholar 

  • Fisher DE, Barnhill R, Hodi FS, Herlyn M, Merlino G, Medrano E et al. (2010). Melanoma from bench to bedside: meeting report from the 6th international melanoma congress. Pigment Cell Melanoma Res 23: 14–26.

    CAS  PubMed  Google Scholar 

  • Flaherty KT, Schiller J, Schuchter LM, Liu G, Tuveson DA, Redlinger M et al. (2008). A phase I trial of the oral, multikinase inhibitor sorafenib in combination with carboplatin and paclitaxel. Clin Cancer Res 14: 4836–4842.

    CAS  PubMed  Google Scholar 

  • Forrester K, Almoguera C, Han K, Grizzle WE, Perucho M . (1987). Detection of high incidence of K-ras oncogenes during human colon tumorigenesis. Nature 327: 298–303.

    CAS  PubMed  Google Scholar 

  • Goel VK, Lazar AJ, Warneke CL, Redston MS, Haluska FG . (2006). Examination of mutations in BRAF, NRAS, and PTEN in primary cutaneous melanoma. J Invest Dermatol 126: 154–160.

    CAS  PubMed  Google Scholar 

  • Gray-Schopfer V, Wellbrock C, Marais R . (2007). Melanoma biology and new targeted therapy. Nature 445: 851–857.

    CAS  PubMed  Google Scholar 

  • Guldberg P, thor Straten P, Birck A, Ahrenkiel V, Kirkin AF, Zeuthen J . (1997). Disruption of the MMAC1/PTEN gene by deletion or mutation is a frequent event in malignant melanoma. Cancer Res 57: 3660–3663.

    CAS  PubMed  Google Scholar 

  • Halaban R, Zhang W, Bacchiocchi A, Cheng E, Parisi F, Ariyan S et al. (2010). PLX4032, a selective BRAFV600E kinase inhibitor, activates the ERK pathway and enhances cell migration and proliferation of BRAFWT melanoma cells. Pigment Cell Melanoma Res 23: 190–200.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Haluska FG, Tsao H, Wu H, Haluska FS, Lazar A, Goel V . (2006). Genetic alterations in signaling pathways in melanoma. Clin Cancer Res 12: 2301s–2307s.

    CAS  PubMed  Google Scholar 

  • Handolias D, Salemi R, Murray W, Tan A, Liu W, Viros A et al. (2010). Mutations in KIT occur at low frequency in melanomas arising from anatomical sites associated with chronic and intermittent sun exposure. Pigment Cell Melanoma Res 23: 210–215.

    CAS  PubMed  Google Scholar 

  • Hatzivassiliou G, Song K, Yen I, Brandhuber BJ, Anderson DJ, Alvarado R et al. (2010). RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature 464: 431–435.

    CAS  PubMed  Google Scholar 

  • Hauschild A, Agarwala SS, Trefzer U, Hogg D, Robert C, Hersey P et al. (2009). Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma. J Clin Oncol 27: 2823–2830.

    CAS  PubMed  Google Scholar 

  • Hauschild A, Gogas H, Tarhini A, Middleton MR, Testori A, Dréno B et al. (2008). Practical guidelines for the management of interferon-alpha-2b side effects in patients receiving adjuvant treatment for melanoma. Cancer 112: 982–994.

    CAS  PubMed  Google Scholar 

  • Heidorn SJ, Milagre C, Whittaker S, Nourry A, Niculescu-Duvas I, Dhomen N et al. (2010). Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell 140: 209–221.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Hingorani SR, Jacobetz MA, Robertson GP, Herlyn M, Tuveson DA . (2003). Suppression of BRAF(V599E) in human melanoma abrogates transformation. Cancer Res 63: 5198–5202.

    CAS  PubMed  Google Scholar 

  • Hirota S, Isozaki K, Moriyama Y, Hashimoto K, Nishida T, Ishiguro S et al. (1998). Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 279: 577–580.

    CAS  PubMed  Google Scholar 

  • Hocker T, Tsao H . (2007). Ultraviolet radiation and melanoma: a systematic review and analysis of reported sequence variants. Hum Mutat 28: 578–588.

    CAS  PubMed  Google Scholar 

  • Hodi FS, Friedlander P, Corless CL, Heinrich MC, Mac Rae S, Kruse A et al. (2008). Major response to imatinib mesylate in KIT-mutated melanoma. J Clin Oncol 26: 2046–2051.

    CAS  PubMed  Google Scholar 

  • Huang S, Luca M, Gutman M, McConkey DJ, Langley KE, Lyman SD et al. (1996). Enforced c-KIT expression renders highly metastatic human melanoma cells susceptible to stem cell factor-induced apoptosis and inhibits their tumorigenic and metastatic potential. Oncogene 13: 2339–2347.

    CAS  PubMed  Google Scholar 

  • Inman JL, Kute T, White W, Pettenati M, Levine EA . (2003). Absence of HER2 overexpression in metastatic malignant melanoma. J Surg Oncol 84: 82–88.

    PubMed  Google Scholar 

  • Jaiswal BS, Janakiraman V, Kljavin NM, Chaudhuri S, Stern HM, Wang W et al. (2009a). Somatic mutations in p85alpha promote tumorigenesis through class IA PI3K activation. Cancer Cell 16: 463–474.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Jaiswal BS, Janakiraman V, Kljavin NM, Eastham-Anderson J, Cupp JE, Liang Y et al. (2009b). Combined targeting of BRAF and CRAF or BRAF and PI3K effector pathways is required for efficacy in NRAS mutant tumors. PLoS One 4: e5717.

    PubMed  PubMed Central  Google Scholar 

  • Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ . (2009). Cancer statistics, 2009. CA Cancer J Clin 59: 225–249.

    PubMed  Google Scholar 

  • Jiang X, Zhou J, Yuen NK, Corless CL, Heinrich MC, Fletcher JA et al. (2008). Imatinib targeting of KIT-mutant oncoprotein in melanoma. Clin Cancer Res 14: 7726–7732.

    CAS  PubMed  Google Scholar 

  • Karasarides M, Chiloeches A, Hayward R, Niculescu-Duvaz D, Scanlon I, Friedlos F et al. (2004). B-RAF is a therapeutic target in melanoma. Oncogene 23: 6292–6298.

    CAS  PubMed  Google Scholar 

  • Katso R, Okkenhaug K, Ahmadi K, White S, Timms J, Waterfield MD . (2001). Cellular function of phosphoinositide 3-kinases: implications for development, homeostasis, and cancer. Annu Rev Cell Dev Biol 17: 615–675.

    CAS  PubMed  Google Scholar 

  • Kim KB, Eton O, Davis DW, Frazier ML, McConkey DJ, Diwan AH et al. (2008). Phase II trial of imatinib mesylate in patients with metastatic melanoma. Br J Cancer 99: 734–740.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Kirkwood J, Strawderman M, Ernstoff M, Smith T, Borden E, Blum R . (1996). Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol 14: 7–17.

    CAS  PubMed  Google Scholar 

  • Kirkwood JM, Manola J, Ibrahim J, Sondak V, Ernstoff MS, Rao U . (2004). A pooled analysis of eastern cooperative oncology group and intergroup trials of adjuvant high-dose interferon for melanoma. Clin Cancer Res 10: 1670–1677.

    CAS  PubMed  Google Scholar 

  • Konstantinopoulos PA, Karamouzis MV, Papavassiliou AG . (2007). Post-translational modifications and regulation of the RAS superfamily of GTPases as anticancer targets. Nat Rev Drug Discov 6: 541–555.

    CAS  PubMed  Google Scholar 

  • Lassam N, Bickford S . (1992). Loss of c-kit expression in cultured melanoma cells. Oncogene 7: 51–56.

    CAS  PubMed  Google Scholar 

  • Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang SI et al. (1997). PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 275: 1943–1947.

    CAS  PubMed  Google Scholar 

  • Maat W, Kilic E, Luyten GPM, de Klein A, Jager MJ, Gruis NA et al. (2008). Pyrophosphorolysis detects B-RAF mutations in primary uveal melanoma. Invest Ophthalmol Vis Sci 49: 23–27.

    PubMed  Google Scholar 

  • Maehama T, Dixon JE . (1998). The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate. J Biol Chem 273: 13375–13378.

    CAS  PubMed  Google Scholar 

  • Margolin K, Longmate J, Baratta T, Synold T, Christensen S, Weber J et al. (2005). CCI-779 in metastatic melanoma: a phase II trial of the California Cancer Consortium. Cancer 104: 1045–1048.

    CAS  PubMed  Google Scholar 

  • Michaloglou C, Vredeveld LC, Soengas MS, Denoyelle C, Kuilman T, van der Horst CM et al. (2005). BRAFE600-associated senescence-like cell cycle arrest of human naevi. Nature 436: 720–724.

    CAS  PubMed  Google Scholar 

  • Montagut C, Sharma SV, Shioda T, McDermott U, Ulman M, Ulkus LE et al. (2008). Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma. Cancer Res 68: 4853–4861.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Myers MP, Pass I, Batty IH, Van der Kaay J, Stolarov JP, Hemmings BA et al. (1998). The lipid phosphatase activity of PTEN is critical for its tumor suppressor function. Proc Natl Acad Sci USA 95: 13513–13518.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Ng SB, Turner EH, Robertson PD, Flygare SD, Bigham AW, Lee C et al. (2009). Targeted capture and massively parallel sequencing of 12 human exomes. Nature 461: 272–276.

    CAS  PubMed  PubMed Central  Google Scholar 

  • O'Reilly KE, Rojo F, She QB, Solit D, Mills GB, Smith D et al. (2006). mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res 66: 1500–1508.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Omholt K, Krockel D, Ringborg U, Hansson J . (2006). Mutations of PIK3CA are rare in cutaneous melanoma. Melanoma Res 16: 197–200.

    CAS  PubMed  Google Scholar 

  • Onken MD, Worley LA, Long MD, Duan S, Council ML, Bowcock AM et al. (2008). Oncogenic mutations in GNAQ occur early in uveal melanoma. Invest Ophthalmol Vis Sci 49: 5230–5234.

    PubMed  Google Scholar 

  • Padua RA, Barrass NC, Currie GA . (1985). Activation of N-ras in a human melanoma cell line. Mol Cell Biol 5: 582–585.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Patton EE, Widlund HR, Kutok JL, Kopani KR, Amatruda JF, Murphey RD et al. (2005). BRAF mutations are sufficient to promote nevi formation and cooperate with p53 in the genesis of melanoma. Curr Biol 15: 249–254.

    CAS  PubMed  Google Scholar 

  • Phan GQ, Attia P, Steinberg SM, White DE, Rosenberg SA . (2001). Factors associated with response to high-dose interleukin-2 in patients with metastatic melanoma. J Clin Oncol 19: 3477–3482.

    CAS  PubMed  Google Scholar 

  • Philp AJ, Campbell IG, Leet C, Vincan E, Rockman SP, Whitehead RH et al. (2001). The phosphatidylinositol 3′-kinase p85alpha gene is an oncogene in human ovarian and colon tumors. Cancer Res 61: 7426–7429.

    CAS  PubMed  Google Scholar 

  • Pleasance ED, Cheetham RK, Stephens PJ, McBride DJ, Humphray SJ, Greenman CD et al. (2010). A comprehensive catalogue of somatic mutations from a human cancer genome. Nature 463: 191–196.

    CAS  PubMed  Google Scholar 

  • Pollock PM, Harper UL, Hansen KS, Yudt LM, Stark M, Robbins CM et al. (2003). High frequency of BRAF mutations in nevi. Nat Genet 33: 19–20.

    CAS  PubMed  Google Scholar 

  • Prickett TD, Agrawal NS, Wei X, Yates KE, Lin JC, Wunderlich JR et al. (2009). Analysis of the tyrosine kinome in melanoma reveals recurrent mutations in ERBB4. Nat Genet 41: 1127–1132.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Quintana E, Shackleton M, Sabel MS, Fullen DR, Johnson TM, Morrison SJ . (2008). Efficient tumour formation by single human melanoma cells. Nature 456: 593–598.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Quintas-Cardama A, Lazar AJ, Woodman SE, Kim K, Ross M, Hwu P . (2008). Complete response of stage IV anal mucosal melanoma expressing KIT Val560Asp to the multikinase inhibitor sorafenib. Nat Clin Pract Oncol 5: 737–740.

    CAS  PubMed  Google Scholar 

  • Rimoldi D, Salvi S, Lienard D, Lejeune FJ, Speiser D, Zografos L et al. (2003). Lack of BRAF mutations in uveal melanoma. Cancer Res 63: 5712–5715.

    CAS  PubMed  Google Scholar 

  • Rivera RS, Nagatsuka H, Gunduz M, Cengiz B, Gunduz E, Siar CH et al. (2008). C-kit protein expression correlated with activating mutations in KIT gene in oral mucosal melanoma. Virchows Arch 452: 27–32.

    CAS  PubMed  Google Scholar 

  • Robertson GP, Furnari FB, Miele ME, Glendening MJ, Welch DR, Fountain JW et al. (1998). In vitro loss of heterozygosity targets the PTEN/MMAC1 gene in melanoma. Proc Natl Acad Sci USA 95: 9418–9423.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Rodenhuis S, van de Wetering ML, Mooi WJ, Evers SG, van Zandwijk N, Bos JL . (1987). Mutational activation of the K-ras oncogene. A possible pathogenetic factor in adenocarcinoma of the lung. N Engl J Med 317: 929–935.

    CAS  PubMed  Google Scholar 

  • Roesch A, Fukunaga-Kalabis M, Schmidt EC, Zabierowski SE, Brafford PA, Vultur A et al. (2010). A temporarily distinct subpopulation of slow-cycling melanoma cells is required for continuous tumor growth. Cell 141: 583–594.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Samuels Y, Wang Z, Bardelli A, Silliman N, Ptak J, Szabo S et al. (2004). High frequency of mutations of the PIK3CA gene in human cancers. Science 304: 554.

    CAS  PubMed  Google Scholar 

  • Schwartz RN, Stover L, Dutcher J . (2002). Managing toxicities of high-dose interleukin-2. Oncology (Williston Park) 16: 11–20.

    Google Scholar 

  • Sjoblom T, Jones S, Wood LD, Parsons DW, Lin J, Barber TD et al. (2006). The consensus coding sequences of human breast and colorectal cancers. Science 314: 268–274.

    PubMed  Google Scholar 

  • Smalley KS, Xiao M, Villanueva J, Nguyen TK, Flaherty KT, Letrero R et al. (2009). CRAF inhibition induces apoptosis in melanoma cells with non-V600E BRAF mutations. Oncogene 28: 85–94.

    CAS  PubMed  Google Scholar 

  • Stahl JM, Sharma A, Cheung M, Zimmerman M, Cheng JQ, Bosenberg MW et al. (2004). Deregulated Akt3 activity promotes development of malignant melanoma. Cancer Res 64: 7002–7010.

    CAS  PubMed  Google Scholar 

  • Steck PA, Pershouse MA, Jasser SA, Yung WK, Lin H, Ligon AH et al. (1997). Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat Genet 15: 356–362.

    CAS  PubMed  Google Scholar 

  • Strumberg D . (2005). Preclinical and clinical development of the oral multikinase inhibitor sorafenib in cancer treatment. Drugs Today (Barc) 41: 773–784.

    CAS  Google Scholar 

  • Suarez HG, Du Villard JA, Caillou B, Schlumberger M, Tubiana M, Parmentier C et al. (1988). Detection of activated ras oncogenes in human thyroid carcinomas. Oncogene 2: 403–406.

    CAS  PubMed  Google Scholar 

  • Sumimoto H, Miyagishi M, Miyoshi H, Yamagata S, Shimizu A, Taira K et al. (2004). Inhibition of growth and invasive ability of melanoma by inactivation of mutated BRAF with lentivirus-mediated RNA interference. Oncogene 23: 6031–6039.

    CAS  PubMed  Google Scholar 

  • Tabernero J, Rojo F, Calvo E, Burris H, Judson I, Hazell K et al. (2008). Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in patients with advanced solid tumors. J Clin Oncol 26: 1603–1610.

    CAS  PubMed  Google Scholar 

  • TCGA (2008). Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455: 1061–1068.

    Google Scholar 

  • Thompson FH, Emerson J, Olson S, Weinstein R, Leavitt SA, Leong SP et al. (1995). Cytogenetics of 158 patients with regional or disseminated melanoma. Subset analysis of near-diploid and simple karyotypes. Cancer Genet Cytogenet 83: 93–104.

    CAS  PubMed  Google Scholar 

  • Torres-Cabala CA, Wang WL, Trent J, Yang D, Chen S, Galbincea J et al. (2009). Correlation between KIT expression and KIT mutation in melanoma: a study of 173 cases with emphasis on the acral-lentiginous/mucosal type. Mod Pathol 22: 1446–1456.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Tsai J, Lee JT, Wang W, Zhang J, Cho H, Mamo S et al. (2008). Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. Proc Natl Acad Sci USA 105: 3041–3046.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Tsao H, Atkins MB, Sober AJ . (2004a). Management of cutaneous melanoma. N Engl J Med 351: 998–1012.

    CAS  PubMed  Google Scholar 

  • Tsao H, Goel V, Wu H, Yang G, Haluska FG . (2004b). Genetic interaction between NRAS and BRAF mutations and PTEN//MMAC1 inactivation in melanoma. J Invest Dermatol 122: 337–341.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Tsao H, Zhang X, Benoit E, Haluska FG . (1998). Identification of PTEN/MMAC1 alterations in uncultured melanomas and melanoma cell lines. Oncogene 16: 3397–3402.

    CAS  PubMed  Google Scholar 

  • Turner EH, Lee C, Ng SB, Nickerson DA, Shendure J . (2009). Massively parallel exon capture and library-free resequencing across 16 genomes. Nat Methods 6: 315–316.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Ugurel S, Hildenbrand R, Zimpfer A, La Rosee P, Paschka P, Sucker A et al. (2005). Lack of clinical efficacy of imatinib in metastatic melanoma. Br J Cancer 92: 1398–1405.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Van Raamsdonk CD, Bezrookove V, Green G, Bauer J, Gaugler L, O'Brien JM et al. (2009). Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi. Nature 457: 599–602.

    CAS  PubMed  Google Scholar 

  • Vivanco I, Sawyers CL . (2002). The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat Rev Cancer 2: 489–501.

    CAS  PubMed  Google Scholar 

  • Wan PTC, Garnett MJ, Roe SM, Lee S, Niculescu-Duvaz D, Good VM et al. (2004). Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 116: 855–867.

    CAS  PubMed  Google Scholar 

  • Woodman SE, Trent JC, Stemke-Hale K, Lazar AJ, Pricl S, Pavan GM et al. (2009). Activity of dasatinib against L576P KIT mutant melanoma: molecular, cellular, and clinical correlates. Mol Cancer Ther 8: 2079–2085.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Wyman K, Atkins MB, Prieto V, Eton O, McDermott DF, Hubbard F et al. (2006). Multicenter phase II trial of high-dose imatinib mesylate in metastatic melanoma: significant toxicity with no clinical efficacy. Cancer 106: 2005–2011.

    CAS  PubMed  Google Scholar 

  • Yazdi AS, Palmedo G, Flaig MJ, Puchta U, Reckwerth A, Rutten A et al. (2003). Mutations of the BRAF gene in benign and malignant melanocytic lesions. J Invest Dermatol 121: 1160–1162.

    CAS  PubMed  Google Scholar 

  • Zhang FL, Kirschmeier P, Carr D, James L, Bond RW, Wang L et al. (1997). Characterization of Ha-ras, N-ras, Ki-Ras4A, and Ki-Ras4B as in vitro substrates for farnesyl protein transferase and geranylgeranyl protein transferase type I. J Biol Chem 272: 10232–10239.

    CAS  PubMed  Google Scholar 

  • Zhao L, Vogt PK . (2008). Class I PI3K in oncogenic cellular transformation. Oncogene 27: 5486–5496.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Zhou XP, Gimm O, Hampel H, Niemann T, Walker MJ, Eng C . (2000). Epigenetic PTEN silencing in malignant melanomas without PTEN mutation. Am J Pathol 157: 1123–1128.

    CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

We thank Darryl Leja for graphical expertize and Nature Genetics for permission to use figures from paper doi:10.1038/ng.438. This work was supported by grants from ASCO (Young Investigator Award) and M D Anderson Cancer Center SPORE in Melanoma (Developmental Research Grant; 5 P50 CA093459 03 PP-DRP3; to MAD) and the Intramural Research Programs of the National Human Genome Research Institute, National Institutes of Health, USA (to YS).

Author information

Authors and Affiliations

  1. Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

    M A Davies

  2. Department of Systems Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

    M A Davies

  3. Cancer Genetics Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, USA

    Y Samuels

Authors
  1. M A Davies
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Y Samuels
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Y Samuels.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Davies, M., Samuels, Y. Analysis of the genome to personalize therapy for melanoma. Oncogene 29, 5545–5555 (2010). https://doi.org/10.1038/onc.2010.323

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/onc.2010.323

Keywords

This article is cited by

Search

Advanced search

Quick links